Danish mega-company Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short of ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...

A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

The drug helped patients reduce their weight by only 22.7 per cent, falling short of the anticipated result. Novo’s shares ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

Novo Nordisk's stock plunges 20% after underwhelming weight-loss trial results for its obesity drug. Analysts say market ...